What patients are you talking about donkey? Machts nicht. * 8 months isn't the right answer for any NWBO group. The composition of the p1 groups is completely unknown. The group that didn't qualifie for the p3 trial is equally unknown since many of them ( how many we don't know) are Pseudoprogressors and "regular" GBM pts avg 14.7 mos according to Stupps (2005 study) but is really about 20 mos in 2015. So help me out what group do you think has 8 month OS?
Not her song. Its Warren Zevon's song . She just covered it years later
It's on the internet it must be true. Do a little more research donkey
Life expectancy isn't 8 months. do your homework. Today's grade ---F
gross margin 90% I want what your smoking pal. Amgen runs at about 80% BUT and its a big but. NWBO is an INDIVIDUALIZED treatment. Thus there will be NO economies of scale with increased demand. Every marginal pt ail cost the exact same as the previous one. Ignoring the fact that DC_VAX is likely to fail. the margins will be in the 40% or so range ( you could look at dndn but you won't.)
Ahh must be another newbie Congrats your post doesn't contain a single accurate statistic. New GBM cases are around 12-14k per year (not 25) ditto for EU. Price to treat (per the COMPANY) will be about 35k (not 100k). Using a meat cleaver multiple like the industry wide price to sale is just foolish. Even you math on the share price using your silly and erroneous data is wrong. NWBO fully dilute share count is about 90-95mm shares
You also completely ignore dilution. The company will be issuing (assuming they can find investors) 20mm dollars worth of shares or so every quarter for at least the next two years or so (about 4 or 5mm shares a quarter at current rates, Call 18mm over the next two years.) Check back when you've done the math.
All this before we even get to the efficacy of DC-Vax.